Browsing Tag
Palsonify
2 posts
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Crinetics Pharmaceuticals shares soar after FDA clears Palsonify, the first oral acromegaly treatment
Crinetics shares surged after FDA approval of Palsonify, the first oral acromegaly therapy. Learn how this launch reshapes patient care and investor sentiment.